<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Interv Aging</journal-id><journal-id journal-id-type="iso-abbrev">Clin Interv Aging</journal-id><journal-title-group><journal-title>Clinical Interventions in Aging</journal-title></journal-title-group><issn pub-type="ppub">1176-9092</issn><issn pub-type="epub">1178-1998</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24039409</article-id><article-id pub-id-type="pmc">3770496</article-id><article-id pub-id-type="doi">10.2147/CIA.S48955</article-id><article-id pub-id-type="publisher-id">cia-8-1133</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>A randomized, double-masked study to evaluate the effect of omega-3 fatty acids supplementation in meibomian gland dysfunction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ole&#x000f1;ik</surname><given-names>Andrea</given-names></name><xref ref-type="aff" rid="af1-cia-8-1133">1</xref><xref ref-type="corresp" rid="c1-cia-8-1133"/></contrib><contrib contrib-type="author"><name><surname>Jim&#x000e9;nez-Alfaro</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="af1-cia-8-1133">1</xref></contrib><contrib contrib-type="author"><name><surname>Alejandre-Alba</surname><given-names>Nicol&#x000e1;s</given-names></name><xref ref-type="aff" rid="af1-cia-8-1133">1</xref></contrib><contrib contrib-type="author"><name><surname>Mahillo-Fern&#x000e1;ndez</surname><given-names>Ignacio</given-names></name><xref ref-type="aff" rid="af2-cia-8-1133">2</xref></contrib></contrib-group><aff id="af1-cia-8-1133"><label>1</label>Department of Ophthalmology, Jim&#x000e9;nez D&#x000ed;az Foundation, Madrid, Spain</aff><aff id="af2-cia-8-1133"><label>2</label>Department of Statistics, Jim&#x000e9;nez D&#x000ed;az Foundation, Madrid, Spain</aff><author-notes><corresp id="c1-cia-8-1133">Correspondence: Andrea Ole&#x000f1;ik, C/Fray Lu&#x000ed;s de Le&#x000f3;n 5A, 3A, 28012, Madrid, Spain, Tel +34 606 16 3328, Fax +34 915 36 0432, Email <email>andreaolemmemel@hotmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><!--Dove Press titles changed from ppub to collections in 2009.
								Fake ppub written to satisfy Coll Date Type=ppub--><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>30</day><month>8</month><year>2013</year></pub-date><volume>8</volume><fpage>1133</fpage><lpage>1138</lpage><permissions><copyright-statement>&#x000a9; 2013 Ole&#x000f1;ik et al, publisher and licensee Dove Medical Press Ltd</copyright-statement><copyright-year>2013</copyright-year><license><license-p>This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Dysfunction of the meibomian gland (MG) is among the most frequent causes of ophthalmological symptoms. The inflammation seen in meibomian gland dysfunction (MGD) is part of its pathogenesis, and evidence of the antioxidant-inflammatory properties of omega-3 fatty acids suggests this to be an appropriate treatment for MGD.</p></sec><sec><title>Objective</title><p>We aimed to assess the effectiveness of omega-3 fatty acids versus placebo, in improving the symptoms and signs of MGD.</p></sec><sec><title>Methods</title><p>We conducted a randomized and double-mask trial of 3 months duration. We enrolled 61 patients who presented with symptomatic MGD and no tear instability (defined as tear breakup time [TBUT] &#x0003c;10 seconds). Participants were randomly assigned to two homogeneous subgroups. For patients in group A, the study treatment included cleaning the lid margins with neutral baby shampoo and use of artificial tears without preservatives, plus a placebo oral agent. For patients in group B, the study treatment included cleaning the lid margins with neutral baby shampoo and use of artificial tears without preservatives, plus oral supplementation with omega-3 fatty acids. We performed the following tests: (1) TBUT; (2) Schirmer I test; (3) Ocular Surface Disease Index&#x000a9; (OSDI&#x000a9;; Allergan, Inc., Irvine, CA, USA); (4) MG expression; (5) evaluation of lid margin inflammation; and (6) interpalpebral and corneal dye staining.</p></sec><sec><title>Results</title><p>After 3 months of evaluation, the mean OSDI, TBUT, lid margin inflammation, and MG expression presented improvement from the baseline values, in group B (<italic>P</italic> &#x0003c; 0.01, <italic>P</italic> &#x0003c; 0.001, <italic>P</italic> &#x0003c; 0.0001, <italic>P</italic> &#x0003c; 0.0001, respectively). The Schirmer test results were also improved and statistically significant (<italic>P</italic> &#x0003c; 0.01).</p></sec><sec><title>Conclusion</title><p>Oral omega-3 fatty acids, 1.5 grams per day, may be beneficial in the treatment of MGD, mainly by improving tear stability.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>blepharitis</kwd><kwd>dry eye</kwd><kwd>ocular inflammation</kwd><kwd>eye discomfort</kwd><kwd>surface disease</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Dysfunction of meibomian gland (MG) is included among the most frequent causes of ophthalmological disorders and is the principal cause of dry eye.<xref ref-type="bibr" rid="b1-cia-8-1133">1</xref> As stated by the report<xref ref-type="bibr" rid="b2-cia-8-1133">2</xref> from an international workshop on MG dysfunction (MGD), the main mechanisms responsible for the development of obstructive MGD are increased meibum viscosity and hyperkeratinization of the ductal epithelium. These processes are influenced by aging, use of contact lenses, topical medications, and hormonal variations. We can also add acinar atrophy and inflammation as common causes of MGD. MGD should be considered as one of the most frequent causes of lipid tear deficiency, responsible for tear instability and for the appreciable shortening of the tear breakup time TBUT.<xref ref-type="bibr" rid="b3-cia-8-1133">3</xref>,<xref ref-type="bibr" rid="b4-cia-8-1133">4</xref></p><p>The regular treatments for MGD comprise: cleansing of the lid, use of artificial tears, topical application of corticosteroids and erythromycin, and oral tetracycline/doxycycline.<sup>35</sup> These measures are usually inefficient and do not effectively target the core mechanism of MGD. Thus, the degenerative processes (eg, hyperkeratosis) of the MG have an important influence in the MGD pathogenesis.</p><p>Tear cytokines also play an important role in chronic inflammation in MGD. When inflammatory cytokine levels in the tears of MGD patients and controls were compared, interleukin (IL)-1&#x003b2;, IL-7, IL-12, IL-17, and macrophage inflammatory protein-1&#x003b2; levels were found to be higher in the MGD patients.<sup>67</sup> Furthermore, IL-6, IL-8, IL-12, tumor necrosis factor (TNF)-&#x003b1; levels, and interferon-&#x003b3; were higher in patients with dysfunctional tear syndrome with MGD, compared with the control group.<xref ref-type="bibr" rid="b8-cia-8-1133">8</xref></p><p>Essential fatty acid supplementation has been shown to have an anti-inflammatory effect on dry eye symptoms.<xref ref-type="bibr" rid="b9-cia-8-1133">9</xref> Fish oil is a source of long-chain omega-3 polyunsaturated fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid. The omega-3 fatty acid EPA and the omega-6 fatty acid arachidonic acid (AA) act competitively as a substrate for both the enzyme cyclooxygenase and the enzyme 5-lipoxygenase. The anti-inflammatory action is believed to result from the synthesis of prostaglandin E3 and leukotriene B5 (LTB5) from EPA that inhibits the conversion of AA to the potentially harmful inflammatory mediator&#x02019;s prostaglandin E2 and leukotriene B4.<xref ref-type="bibr" rid="b10-cia-8-1133">10</xref></p><p>In the present study, we evaluated the effectiveness of oral supplementation with a combined formulation of antioxidants and omega-3 in improving the signs and symptoms of diagnosed MGD, compared with placebo.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This randomized, double-masked study/trial was performed with the approval of the ethics committee and the institutional review boards of the University Hospital Jim&#x000e9;nez D&#x000ed;az Foundation (Madrid, Spain). All tenets of the Declaration of Helsinki for the protection of human subjects in medical research were strictly observed.</p><sec sec-type="methods"><title>Study design</title><p>A total of 61 subjects of both sexes, aged 23&#x02013;85 years, were enrolled during ophthalmologic appointments at the study center, the University Hospital Jim&#x000e9;nez D&#x000ed;az Foundation in Madrid, Spain, between March 2012 and December 2012, according to the main inclusion/exclusion criteria listed in <xref ref-type="table" rid="t1-cia-8-1133">Table 1</xref>.</p><p>Prior to the baseline visit, subjects were required to discontinue use of nutritional supplements and related treatments, such as antibiotics, nonsteroidal anti-inflammatory drugs, corticosteroids, and tears with vitamins, for at least 15 days. Participants were asked to strictly follow the recommendations of the ophthalmologists throughout the duration of the study. Ocular lubricants without nutritional agents were not restricted. Patients with obvious infection were excluded from the present study. Patients diagnosed with MGD were enrolled, according to criteria identified at a 2011 international workshop on MGD.<xref ref-type="bibr" rid="b11-cia-8-1133">11</xref></p><p>To classify our study participants, we performed systematic ophthalmologic examinations and administered a questionnaire with objective and subjective criteria. At the baseline visit (month 0), patients were checked for signs and symptoms of MGD, and we applied the inclusion and exclusion criteria of the trial protocol. The assessed baseline parameters were: (1) TBUT; (2) tear quantification, (Schirmer I test);<xref ref-type="bibr" rid="b3-cia-8-1133">3</xref>,<xref ref-type="bibr" rid="b4-cia-8-1133">4</xref> (3) Ocular Surface Disease Index&#x000a9; (OSDI) (American Optometric Association, St Louis, MO, USA); (4) MG expression and secretion; (5) lid margin inflammation evaluation; (6) interpalpebral and corneal dye staining; and (7) fluorescein stain of the cornea. Furthermore, patients used a daily tear complement without preservatives, which was measured. All participants were required, on a daily basis, to apply a warm compress for 5 minutes and to scrub the eye with diluted baby shampoo.</p><p>All participants additionally took an oral agent (one capsule taken with each of the three main meals per day). The participants were randomly assigned to group A or group B. Group A patients received a placebo oral supplement: 500 mg capsules incorporating sunflower oil with no other components or excipients apart from gelatin (bovine) and titanium oxide colorants, iron oxide, and hydroxides. Participants in group B received the study oral supplement formulation (Brudysec 1.5 g; Brudy Lab SL, Barcelona, Spain) reported in <xref ref-type="table" rid="t2-cia-8-1133">Table 2</xref>. The supplement for group B was based on omega-3, vitamins, glutathione, amino acids, and oligoelements in a combined nutraceutical formulation and contained (per capsule) docosahexaenoic acid (350 mg), eicosapentaenoic acid (42.5 mg), docosapentaenoic acid (30 mg), vitamin A (133.3 &#x003bc;g), vitamin C (26.7 mg), vitamin E (4 mg), tyrosine (10.8 mg), cysteine (5.83 mg), glutathione (2 mg), zinc (1.6 mg), copper (0.16 mg), manganese (0.33 mg), and selenium (9.17 &#x003bc;g).</p><p>The objective factors were reassessed at follow-up visits 1, 2, and 3 months after the assigned treatments began. The objective factors were evaluated by one investigator (AO) to reduce interobserver variability. We assumed a self-administered medical therapy has only 50% adherence, so at each visit, the patients were required to deliver the empty boxes of medication received, in order to improve compliance as well as to ensure the validity of the final data of the study. Subjects were followed up monthly, for 3 months after the initial visit.</p></sec><sec><title>Patient management</title><p>Personal interviews were conducted with all participants to obtain their personal and familial backgrounds and characteristics of their disease, mainly symptoms of MGD. The OSDI questionnaire assessed the frequency of dry eye symptoms and problems with the ocular surface.<xref ref-type="bibr" rid="b12-cia-8-1133">12</xref> The OSDI assessed the participants&#x02019; condition as normal, mild, moderate, or severe.</p><p>All participants underwent a systematic ophthalmologic examination to determine best corrected visual acuity in each eye. The objective signs were evaluated by means of a slit-lamp IS-600II Topcon (Topcon Corporation, Tokyo, Japan) examination (lid margin inflammation and MG expression), staining of the conjunctiva and cornea with fluorescein (Oxford Test),<xref ref-type="bibr" rid="b13-cia-8-1133">13</xref> measurement of TBUT,<xref ref-type="bibr" rid="b3-cia-8-1133">3</xref>,<xref ref-type="bibr" rid="b4-cia-8-1133">4</xref> and the quantification of the tear assessed by Schirmer I test. Lid margin inflammation severity was scored: 0, no injection; 1, injection (presence of conjunctival vessels congestion and/or hyperemia) (<xref ref-type="table" rid="t3-cia-8-1133">Table 3</xref>).</p><p>MGD was defined as abnormal discharge and/or anomalous expression when a finger was placed on both palpebral lids: clear fluid, cloudy fluid, cloudy particulate fluid, or inspissated and toothpaste-like (<xref ref-type="table" rid="t3-cia-8-1133">Table 3</xref>).<xref ref-type="bibr" rid="b1-cia-8-1133">1</xref> The primary ophthalmologic outcome measures for effectiveness of the oral nutraceutical formulation were fluorescein staining and TBUT; the secondary measures were Schirmer I test and dry eye symptoms.<xref ref-type="bibr" rid="b12-cia-8-1133">12</xref></p><p>TBUT was measured by instillation of one drop of 2% fluorescein. The time until disappearance of the dye was recorded, and the average of three trials was calculated. On the other hand, we used the Oxford Test in order to evaluate the corneal fluorescein. Also, the Schirmer I test (quantification of the tear) was applied during a 5 minute interval, without anesthesia. We evaluated the safety outcomes by means of ophthalmological explorations, and any adverse events that occurred, during the whole of the research.</p></sec><sec sec-type="methods"><title>Statistical analysis</title><p>We analyzed the outcomes of patients&#x02019; right eyes. The most significant results came from the TBUT test. Statistics are reported as mean values and standard deviations. We used dependent-samples Student&#x02019;s <italic>t</italic> (TBUT and Schirmer), McNemar (inflammation of the lids and expression of the MG), and Wilcoxon tests (OSDI and Oxford) for intragroup and intergroup comparisons. Both intragroup and intergroup comparisons were made with an intention-to-treat analysis. <italic>P</italic>-values (two-sided) less than 0.05 were considered statistically significant. Statistical analyses were performed with the Statistical Package for the Social Sciences, Version 11.0 software (SPSS, Inc., Chicago, IL, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patient demographics</title><p>We recruited 64 patients in the research; 31 were assigned to group A, and 33 were assigned to group B. Three patients (from group B) were withdrawn from the study: two (3.12%) because of drug intolerance, and one (1.56%) did not pursue the treatment.</p><p>Sixty-one patients completed the study: 31 (50.82%) in group A and 30 (49.18%) in group B. The mean age of the group B patients was 58 years and was 54 years for group A. Most of the patients involved in the study were women, but we did not observe significant differences in the sex distribution for both groups.</p><p>Additionally, we did not observe significant intergroup differences in baseline signs and symptoms. <xref ref-type="table" rid="t3-cia-8-1133">Table 3</xref> summarizes the baseline data, including demography, and the signs and symptoms. Throughout the randomized study, the investigators and patients were blinded to the treatment assignments.</p></sec><sec><title>Treatment responses</title><p>At baseline, the mean TBUT was 6.45 (2.57) seconds and 6.94 (2.75) seconds for groups A and B, respectively (<xref ref-type="table" rid="t3-cia-8-1133">Table 3</xref>). At each monitoring, the mean TBUT for group B was greater than the baseline and the group A values. The TBUT at the final follow-up visit was 8.03 (2.86) seconds and 12.63 (1.75) seconds in group A and in group B, respectively (<italic>P</italic> &#x0003c; 0.01) (<xref ref-type="fig" rid="f1-cia-8-1133">Figure 1</xref>).</p><p>In the control group (group A), the TBUT did not change significantly from baseline. However in group B, lid inflammation was decreased significantly compared with baseline, at each follow-up (<italic>P</italic> &#x0003c; 0.0001).</p><p>In group B, the MG expressibility was significantly greater than baseline, at 1 month (<italic>P</italic> = 0.01) and at 3 months (<italic>P</italic> &#x0003c; 0.0001); group A did not present a change in expressibility.</p><p>In both groups, cornea staining data presented no significant differences from baseline, although the group B results were lower at each monitored visit.</p><p>The mean tear quantification was assessed by the Schirmer I test, without anesthesia. At baseline, this was 16.61 (7.57) mm in group A and 18.94 (7.47) mm in group B. The tear quantification results at 3 months were not significantly different from baseline in either group.</p><p>The dysfunctions of the tear were evaluated using the OSDI test. Both groups exhibited a decrease in tear dysfunction symptoms in group B, the decrease was observed at 1 month and 3 months (<italic>P</italic> = 0.01 and <italic>P</italic> = 0.09, respectively), and in group A, this was also observed at both of the follow-up visits (<italic>P</italic> = 0.09 and <italic>P</italic> = 0.003, respectively).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The main cause of MGD is hyperkeratinization and its related pathogenesis (for example, ductal dilatation and acinar atrophy). Other pathologies, such as atopy, pemphigoid acne rosacea, and seborrhea are related to MGD and may result in a chronic inflammation of the ocular surface.<xref ref-type="bibr" rid="b14-cia-8-1133">14</xref> Thus, all these circumstances may also lead to dry eye, the alteration of the tear, and irritation of the eye shown by MGD patients.</p><p>Furthermore, other factors, such as: IL-6, IL-8, IL-12, TNF-&#x003b1; levels, and interferon-&#x003b3;may be increased in MGD;<xref ref-type="bibr" rid="b8-cia-8-1133">8</xref>,<xref ref-type="bibr" rid="b15-cia-8-1133">15</xref> the latter may explain the irritation and lid inflammation symptoms noticed in patients with this disorder. Based on these effects, inflammatory properties may be targeted in the treatment of MGD.</p><p>The anti-inflammatory power of essential polyunsaturated fatty acids used in treatment of the ocular surface may be compared with corticosteroids, as they act as the same mediator, through nuclear factor kappa B <sc>(NF-</sc><sc>&#x003ba;</sc><sc>B)</sc> signal transduction, of the inflammation cascade.<xref ref-type="bibr" rid="b16-cia-8-1133">16</xref> The inflammation at the lid margin presented improvement from the baseline in group B (who took the omega-3 fatty acids supplement), and consequently, this study suggests that omega-3 fatty acids may improve tear film stability, decrease the inflammation of lid margins, and recover the homeostasis of ocular surface in patients with MGD.</p><p>Wojtowicz et al<xref ref-type="bibr" rid="b17-cia-8-1133">17</xref> did not find statistically significant differences between omega-3 and placebo in the treatment of dry eye; nevertheless, we did find statistically significant differences in our assessment of the TBUT test after treatment with omega-3 for MGD. This study is a starting point for further research into the benefit of omega-3 fatty acids for inflammatory disease of the ocular surface, and other studies should aim to quantify the beneficial effect of omega-3 fatty acids in MGD with evaporative dry eye, for example, by incrementally increasing the dose of omega-3 fatty acids and assessing the anti-inflammatory effect. We should also consider other research improvements, for eg, balancing the ratio of males to females in the study population.</p><p>A strength of this research is that it was randomized and double-masked, which may have minimized any partiality. The main outcome measure of efficacy was tear film stability, and greater differences might have been observed in a larger patient sample. A larger, controlled, and multicenter study may be required in order to confirm whether this improvement in tear stability is applicable to clinical practice.</p></sec><sec><title>Adverse events</title><p>No serious adverse events arose during the research. Of 64 patients, two patients (3.12%) in the preliminary-stage (intention-to-treat) analysis group reported digestive upset with omega-3 treatment. These symptoms arose within the first month of treatment, and the patients recovered immediately after stopping the medication.</p></sec><sec><title>Conclusion</title><p>To conclude, this research established that omega-3 fatty acids, 1.5 g, can increase TBUT in subjects with MGD. Thus, when conventional treatment (artificial tears) has proven unsatisfactory for patients with MGD, omega-3 fatty acids, 1.5 g, may be an effective adjunctive treatment.</p></sec></body><back><ack><title>Acknowledgments</title><p>The food supplements used this trial were provided by Brudy Lab SL, Barcelona, Spain.</p></ack><fn-group><fn><p><bold>Disclosure</bold></p><p>The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-cia-8-1133"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foulks</surname><given-names>GN</given-names></name><name><surname>Bron</surname><given-names>AJ</given-names></name></person-group><article-title>Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading</article-title><source>Ocul Surf</source><year>2003</year><volume>1</volume><issue>3</issue><fpage>107</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">17075643</pub-id></element-citation></ref><ref id="b2-cia-8-1133"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knop</surname><given-names>E</given-names></name><name><surname>Knop</surname><given-names>N</given-names></name><name><surname>Millar</surname><given-names>T</given-names></name><name><surname>Obata</surname><given-names>H</given-names></name><name><surname>Sullivan</surname><given-names>DA</given-names></name></person-group><article-title>The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><issue>4</issue><fpage>1938</fpage><lpage>1978</lpage><pub-id pub-id-type="pmid">21450915</pub-id></element-citation></ref><ref id="b3-cia-8-1133"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Mathers</surname><given-names>WD</given-names></name></person-group><article-title>Meibomian gland disease</article-title><person-group person-group-type="editor"><name><surname>Pflugfelder</surname><given-names>SC</given-names></name><name><surname>Beuerman</surname><given-names>RW</given-names></name><name><surname>Stern</surname><given-names>ME</given-names></name></person-group><source>Dry Eye and Ocular Surface Disorders</source><publisher-loc>New York, NY</publisher-loc><publisher-name>Marcel Dekker Inc</publisher-name><year>2004</year><fpage>247</fpage><lpage>267</lpage></element-citation></ref><ref id="b4-cia-8-1133"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driver</surname><given-names>PJ</given-names></name><name><surname>Lemp</surname><given-names>MA</given-names></name></person-group><article-title>Meibomian gland dysfunction</article-title><source>Surv Ophthalmol</source><year>1996</year><volume>40</volume><issue>5</issue><fpage>343</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">8779082</pub-id></element-citation></ref><ref id="b5-cia-8-1133"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bron</surname><given-names>AJ</given-names></name><name><surname>Benjamin</surname><given-names>L</given-names></name><name><surname>Snibson</surname><given-names>GR</given-names></name></person-group><article-title>Meibomian gland disease. Classification and grading of lid changes</article-title><source>Eye (Lond)</source><year>1991</year><volume>5</volume><issue>Pt 4</issue><fpage>395</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">1743355</pub-id></element-citation></ref><ref id="b6-cia-8-1133"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name></person-group><article-title>Tear cytokines and chemokines in patients with Demodex blepharitis</article-title><source>Cytokine</source><year>2011</year><volume>53</volume><issue>1</issue><fpage>94</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">21050771</pub-id></element-citation></ref><ref id="b7-cia-8-1133"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Dursun</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Macri</surname><given-names>A</given-names></name><name><surname>Pflugfelder</surname><given-names>SC</given-names></name></person-group><article-title>Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease</article-title><source>Invest Ophthalmol Vis Sci</source><year>2001</year><volume>42</volume><issue>10</issue><fpage>2283</fpage><lpage>2292</lpage><pub-id pub-id-type="pmid">11527941</pub-id></element-citation></ref><ref id="b8-cia-8-1133"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>H</given-names></name><name><surname>Bleiden</surname><given-names>L</given-names></name><name><surname>de Paiva</surname><given-names>CS</given-names></name><name><surname>Farley</surname><given-names>W</given-names></name><name><surname>Stern</surname><given-names>ME</given-names></name><name><surname>Pflugfelder</surname><given-names>SC</given-names></name></person-group><article-title>Tear cytokine profiles in dysfunctional tear syndrome</article-title><source>Am J Ophthalmol</source><year>2009</year><volume>147</volume><issue>2</issue><fpage>198</fpage><lpage>205</lpage><comment>e1</comment><pub-id pub-id-type="pmid">18992869</pub-id></element-citation></ref><ref id="b9-cia-8-1133"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brignole-Baudouin</surname><given-names>F</given-names></name><name><surname>Baudouin</surname><given-names>C</given-names></name><name><surname>Aragona</surname><given-names>P</given-names></name><etal/></person-group><article-title>A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients</article-title><source>Acta Ophthalmol</source><year>2011</year><volume>89</volume><issue>7</issue><fpage>e591</fpage><lpage>e597</lpage><pub-id pub-id-type="pmid">21834921</pub-id></element-citation></ref><ref id="b10-cia-8-1133"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>MJ</given-names></name><name><surname>Gibson</surname><given-names>RA</given-names></name><name><surname>Cleland</surname><given-names>LG</given-names></name></person-group><article-title>Dietary polyunsaturated fatty acids and inflammatory mediator production</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>71</volume><issue>Suppl 1</issue><fpage>343S</fpage><lpage>348S</lpage><pub-id pub-id-type="pmid">10617994</pub-id></element-citation></ref><ref id="b11-cia-8-1133"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomlinson</surname><given-names>A</given-names></name><name><surname>Bron</surname><given-names>AJ</given-names></name><name><surname>Korb</surname><given-names>DR</given-names></name><etal/></person-group><article-title>The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><issue>4</issue><fpage>2006</fpage><lpage>2049</lpage><pub-id pub-id-type="pmid">21450918</pub-id></element-citation></ref><ref id="b12-cia-8-1133"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffman</surname><given-names>RM</given-names></name><name><surname>Christianson</surname><given-names>MD</given-names></name><name><surname>Jacobsen</surname><given-names>G</given-names></name><name><surname>Hirsch</surname><given-names>JD</given-names></name><name><surname>Reis</surname><given-names>BL</given-names></name></person-group><article-title>Reliability and validity of the Ocular Surface Disease Index</article-title><source>Arch Ophthalmol</source><year>2000</year><volume>118</volume><issue>5</issue><fpage>615</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">10815152</pub-id></element-citation></ref><ref id="b13-cia-8-1133"><label>13</label><mixed-citation publication-type="journal"><article-title>Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye Workshop</article-title><source>Ocular Surface</source><year>2007</year><month>4</month><volume>5</volume><issue>2</issue><fpage>108</fpage><lpage>152</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pubmed/17508118">http://www.ncbi.nlm.nih.gov/pubmed/17508118</ext-link></comment>Accessed <date-in-citation>July 1, 2013</date-in-citation><pub-id pub-id-type="pmid">17508118</pub-id></mixed-citation></ref><ref id="b14-cia-8-1133"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nichols</surname><given-names>KK</given-names></name><name><surname>Foulks</surname><given-names>GN</given-names></name><name><surname>Bron</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The international workshop on meibomian gland dysfunction: executive summary</article-title><source>Invest Ophthalmol Vis Sci</source><year>2011</year><volume>52</volume><issue>4</issue><fpage>1922</fpage><lpage>1929</lpage><pub-id pub-id-type="pmid">21450913</pub-id></element-citation></ref><ref id="b15-cia-8-1133"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enr&#x000ed;quez-de-Salamanca</surname><given-names>A</given-names></name><name><surname>Castellanos</surname><given-names>E</given-names></name><name><surname>Stern</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease</article-title><source>Mol Vis</source><year>2010</year><volume>16</volume><fpage>862</fpage><lpage>873</lpage><pub-id pub-id-type="pmid">20508732</pub-id></element-citation></ref><ref id="b16-cia-8-1133"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdinest</surname><given-names>N</given-names></name><name><surname>Shmueli</surname><given-names>O</given-names></name><name><surname>Grossman</surname><given-names>Y</given-names></name><name><surname>Ovadia</surname><given-names>H</given-names></name><name><surname>Solomon</surname><given-names>A</given-names></name></person-group><article-title>Anti-inflammatory effects of alpha linolenic acid on human corneal epithelial cells</article-title><source>Invest Ophthalmol Vis Sci</source><year>2012</year><volume>53</volume><issue>8</issue><fpage>4396</fpage><lpage>4406</lpage><pub-id pub-id-type="pmid">22669722</pub-id></element-citation></ref><ref id="b17-cia-8-1133"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wojtowicz</surname><given-names>JC</given-names></name><name><surname>Butovich</surname><given-names>I</given-names></name><name><surname>Uchiyama</surname><given-names>E</given-names></name><name><surname>Aronowicz</surname><given-names>J</given-names></name><name><surname>Agee</surname><given-names>S</given-names></name><name><surname>McCulley</surname><given-names>JP</given-names></name></person-group><article-title>Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye</article-title><source>Cornea</source><year>2011</year><volume>30</volume><issue>3</issue><fpage>308</fpage><lpage>314</lpage><pub-id pub-id-type="pmid">21045648</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-cia-8-1133" position="float"><label>Figure 1</label><caption><p>Changes in mean tear breakup time, from baseline to month 3, in subjects assigned to omega-3 or placebo.</p><p><bold>Note:</bold> The differences between month 3 and baseline values were statistically significant (<italic>P</italic> &#x0003c; 0.001).</p><p><bold>Abbreviation:</bold> TBUT, tear breakup time; s, seconds.</p></caption><graphic xlink:href="cia-8-1133Fig1"/></fig><table-wrap id="t1-cia-8-1133" position="float"><label>Table 1</label><caption><p>Inclusion and exclusion criteria</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Inclusion criteria</th><th align="left" valign="top" rowspan="1" colspan="1">Exclusion criteria</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Aged 18&#x02013;85 years</td><td align="left" valign="top" rowspan="1" colspan="1">Aged &#x0003c;23 years or &#x0003e;85 years</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnosed with MGD</td><td align="left" valign="top" rowspan="1" colspan="1">Atopy, allergic disorders</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Able to participate in the study</td><td align="left" valign="top" rowspan="1" colspan="1">Contact lenses</td></tr><tr><td align="left" valign="top" rowspan="7" colspan="1">Informed consent</td><td align="left" valign="top" rowspan="1" colspan="1">Ophthalmic laser treatment (less than 3 months) Systemic diseases and general treatments Pregnancy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systemic diseases and general treatments Pregnancy</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Systemic disease associated with dry eye</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Blepharitis without MGD diagnosis</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ocular disorders and eye drops other than artificial tears</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Unable to participate in the study</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-cia-8-1133"><p><bold>Abbreviation:</bold> MGD, meibomian gland dysfunction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-cia-8-1133" position="float"><label>Table 2</label><caption><p>Composition of Brudysec 1.5 g (Brudy Lab SL, Barcelona, Spain), per capsule</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Nutrient</th><th align="left" valign="top" rowspan="1" colspan="1">Amount</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">DHA</td><td align="left" valign="top" rowspan="1" colspan="1">350 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EPA</td><td align="left" valign="top" rowspan="1" colspan="1">42.5 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin A</td><td align="left" valign="top" rowspan="1" colspan="1">133.3 &#x003bc;g</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin C</td><td align="left" valign="top" rowspan="1" colspan="1">26.7 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin E</td><td align="left" valign="top" rowspan="1" colspan="1">4 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tyrosine</td><td align="left" valign="top" rowspan="1" colspan="1">10.8 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cysteine</td><td align="left" valign="top" rowspan="1" colspan="1">5.83 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glutathione</td><td align="left" valign="top" rowspan="1" colspan="1">2 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zinc</td><td align="left" valign="top" rowspan="1" colspan="1">1.6 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Copper</td><td align="left" valign="top" rowspan="1" colspan="1">0.16 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Manganese</td><td align="left" valign="top" rowspan="1" colspan="1">0.33 mg</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Selenium</td><td align="left" valign="top" rowspan="1" colspan="1">9.17 &#x003bc;g</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DPA</td><td align="left" valign="top" rowspan="1" colspan="1">30 mg</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-cia-8-1133"><p><bold>Abbreviations:</bold> DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-cia-8-1133" position="float"><label>Table 3</label><caption><p>Baseline patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th><th align="left" valign="top" rowspan="1" colspan="1">Placebo (group A; n = 31)</th><th align="left" valign="top" rowspan="1" colspan="1">Omega-3 (group B; n = 33)</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Sex</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Male, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (29.03)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (27.2)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Female, n (%)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (70.97)</td><td align="left" valign="top" rowspan="1" colspan="1">24 (72.8)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age in years, mean</td><td align="left" valign="top" rowspan="1" colspan="1">54</td><td align="left" valign="top" rowspan="1" colspan="1">58</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Signs</bold></td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Lid margin inflammation severity, n (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No injection</td><td align="left" valign="top" rowspan="1" colspan="1">9 (29.03)</td><td align="left" valign="top" rowspan="1" colspan="1">10 (30.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Injection</td><td align="left" valign="top" rowspan="1" colspan="1">22 (70.97)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (69.7)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Meibomian gland secretion, n (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Clear fluid</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.22)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (12.12)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Cloudy fluid</td><td align="left" valign="top" rowspan="1" colspan="1">21 (67.74)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (60.60)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Cloudy particulate fluid</td><td align="left" valign="top" rowspan="1" colspan="1">6 (19.35)</td><td align="left" valign="top" rowspan="1" colspan="1">8 (24.24)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Inspissated, like toothpaste</td><td align="left" valign="top" rowspan="1" colspan="1">3 (9.68)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (3.03)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No secretion</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean TBUT (SD), s</td><td align="left" valign="top" rowspan="1" colspan="1">6.45 (2.57)</td><td align="left" valign="top" rowspan="1" colspan="1">6.94 (2.75)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean Schirmer I (SD), mm</td><td align="left" valign="top" rowspan="1" colspan="1">16.61 (7.57)</td><td align="left" valign="top" rowspan="1" colspan="1">18.94 (7.47)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">Cornea staining data. Oxford test, n (%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grade 0</td><td align="left" valign="top" rowspan="1" colspan="1">23 (74.2)</td><td align="left" valign="top" rowspan="1" colspan="1">22 (66.7)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grade I</td><td align="left" valign="top" rowspan="1" colspan="1">5 (16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (33.3)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Grade II to IV</td><td align="left" valign="top" rowspan="1" colspan="1">3 (9.7)</td><td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><bold>Symptoms</bold></td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1">OSDI&#x000a9;</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Normal</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Mild</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Moderate</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">17</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Severe</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">12</td></tr></tbody></table><table-wrap-foot><fn id="tfn3-cia-8-1133"><p><bold>Abbreviations:</bold> OSDI&#x000a9;, Ocular Surface Disease Index; SD, standard deviation; TBUT, tear breakup time; s, seconds.</p></fn></table-wrap-foot></table-wrap></floats-group></article>